The January/February issue of NeuroPerspective for 2017 has now been published. The issue is our Annual Overview of the neurotherapeutics sector, with capsule reviews for 110 CNS companies of all sizes, a review of deal and funding trends; Highlights and Lowlights from 2016; as well as an assessment of major events coming up this year. The review provides insightful, candid commentary about a wide range of issues pertinent to the development of therapeutics for neurology and psychiatry, including the current climate for investment and partnership funding; an updated assessment of the amyloid hypothesis in Alzheimer’s; US governmental elements to be monitored; threats to the credibility of the biopharma industry; a Company Spotlight Review for EIP Pharma; and many more topics.
Some of the companies included in the Annual Overview are:
Acadia Pharmaceuticals, AC Immune, Acorda Therapeutics, Adamas Pharmaceuticals, AgeneBio, Alcobra, Alector, Alkahest, Alkermes, Allergan, Alzheon, American Life Sciences Pharmaceutical, Amgen, AMO Pharma, Amorsa Therapeutics, Anavex Life Sciences, Anelixis Therapeutics, Annexon, Aptinyx, Asceneuron, Astellas, AstraZeneca, Avanir, AveXis, Axial Biotherapeutics, Axon-Neuroscience, Axovant, Axsome, Azevan, BioAxone, Biogen, Biohaven Pharmaceuticals, Bionomics, Blackthorn Therapeutics, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Cara Therapeutics, Catalyst Pharmaceuticals, Centrexion, Cerecor, Cortexyme, Denali Therapeutics, Depomed, Egalet, EIP Pharma, Eisai, Embera Therapeutics, Evotec, Flex Pharma, Genentech, Gliacure, GSK, GW Pharmaceuticals, Heptares Therapeutics, Intra-Cellular Therapies, Innate Immunotherapeutics, Ionis Pharmaceuticals, JNJ/Janssen, Lilly, Lundbeck, Lysosomal Therapeutics, Marinus Pharmaceuticals, MedGenics, Merck, Methylation Sciences, Minerva Neurosciences, Mitsubishi Tanabe, Neuren Pharmaceuticals, Neurocrine Biosciences, Newron, Novartis, Otsuka, Ovid Therapeutics, Pfizer, Prana Biotechnology, Probiodrug, Proclara Biosciences, Purdue Pharma, ReNeuron, RespireRx, Roche, SAGE Therapeutics, Sanofi/Genzyme, Sunovion, Supernus, Takeda,TauRx, Tetra Discovery,Teva Pharmaceuticals,Trevena, UCB Pharma, Voyager Therapeutics, Wex Pharma, Xenon, Yumanity Therapeutics, Zogenix, Zynerba